Effect of Acute and Chronic Administration of Calcitonin on Serum Glucose in Patients with Paget's Disease of Bone*

Gattereau, A; Bielmann, P; Durivage, J; Davignon, Jean; Larochelle, Pierre

doi:10.1210/jcem-51-2-354

Cited by 17 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To answer this question, we observed the responses of plasma glucagon and catecholamines to exogenous CGRP because these substances are major physiological factors possessing hyperglycemic activity. On the other hand, CGRP, like calcitonin, is known to have a hypocalcemic action (19), and changes in plasma Ca 2+ levels have been reported to affect glucose metabolism (20). In this study, however, plasma glucagon levels were not responsible for the CGRP-induced hyperglycemia.…”

Section: -contrasting

confidence: 58%

Calcitonin Gene—Related Peptide and Induction of Hyperglycemia in Conscious Rats In Vivo

Yamaguchi

Chiba²,

Morishita

et al. 1990

Diabetes

View full text Add to dashboard Cite

The effect of calcitonin gene-related peptide (CGRP) on glucose metabolism was investigated in conscious and unrestrained rats in vivo. Intravenous injection of rat CGRP (5.67 and 0.567 nmol/kg) caused a significant, dose-dependent increase in plasma glucose concentration and a simultaneous dose-dependent increase in plasma insulin level. In contrast, plasma glucagon level was not changed. On the other hand, intravenous infusion of CGRP (46.6 pmol.kg-1.min-1) decreased tolerance to intragastric administration of glucose (IGGTT). Plasma insulin response to IGGTT, however, was not affected by CGRP infusion. Moreover, although intravenous injection of CGRP (5.67 nmol/kg) elicited a significant increase in plasma epinephrine and norepinephrine concentrations, concomitant administration of epinephrine and norepinephrine, inducing a more prominent rise in plasma catecholamines than those induced by CGRP, affected neither plasma glucose nor insulin levels. Finally, plasma insulin levels obtained by simulating CGRP-induced changes in plasma glucose or glucose plus catecholamine levels by infusion of glucose or glucose plus catecholamines were not different from those induced by CGRP injection. These results suggest that CGRP has a hyperglycemic action that is not mediated by sympathetic outflow in conscious rats, and inhibition of insulin secretion, if any, does not play a major role in this hyperglycemic action of CGRP. We have demonstrated specific CGRP receptors linked to adenylate cyclase activation in rat liver plasma membranes; this hyperglycemic effect of CGRP in vivo may be partly due to its direct action on the liver.

show abstract

Section: -contrasting

confidence: 58%

Calcitonin Gene—Related Peptide and Induction of Hyperglycemia in Conscious Rats In Vivo

Yamaguchi

Chiba²,

Morishita

et al. 1990

Diabetes

View full text Add to dashboard Cite

show abstract

“…With respect to salmon calcitonin, In clinical settings, it was shown to reduce glucose clearance [119][120][121][122][123], most probably by inhibition of insulin secretion through binding to amylin receptors in brain, and by stimulation of glycogenolysis in skeletal muscle [116]. However, sCT in its injectable form has also been shown to reduce glucose and insulin levels in insulin-dependent diabetes [124].…”

Section: Other Indicationsmentioning

confidence: 99%

Oral salmon calcitonin – pharmacology in osteoporosis

Henriksen¹,

Bay‐Jensen²,

Christiansen³

et al. 2010

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…DACRAs and amylin have been shown to be diabetogenic in acute studies in humans (Petralito et al, 1979;Gattereau et al, 1980;Passariello et al, 1981) and rats and is linked to plasma lactate (Young et al, 1991(Young et al, , 1995Gydesen et al, 2016;Hjuler et al, 2016). The diabetogenic effect is however transient and is no longer evident with continuous dosing (Giustina et al, 1985;Gydesen et al, 2016;Hjuler et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action

Sonne

Larsen

Andreassen

et al. 2020

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Pharmacological treatment with dual amylin and calcitonin receptor agonists (DACRAs) cause significant weight loss and improvement of glucose homeostasis. In this study, the maximally efficacious dose of the novel DACRA, KeyBiosciencePeptide (KBP)-066, was investigated. Two different rat models were used: high-fat diet (HFD)-fed male Sprague-Dawley rats and male Zucker diabetic fatty (ZDF, fa/fa) rats to determine the maximum weight loss and glucose homeostatic effect, respectively. One acute study and one chronic study was performed in HFD rats. Two chronic studies were performed in ZDF rats: a preventive and an interventive. All studies covered a dose range of 5, 50, and 500 mg/kg KBP-066 delivered by subcutaneous injection. Treatment with KBP-066 resulted in a significant weight reduction of 13%-16% and improved glucose tolerance in HFD rats, which was independent of dose concentration. Dosing with 50 and 500 mg/kg led to a transient but significant increase in blood glucose, both in the acute and the chronic study in HFD rats. All doses of KBP-066 significantly improved glucose homeostasis in ZDF rats, both in the preventive and interventive study. Moreover, dosing with 50 and 500 mg/kg preserved insulin secretion to a greater extent than 5 mg/kg when compared with ZDF vehicle rats. Taken together, these results show that maximum weight loss is achieved with 5 mg/kg, which is within the range of previously reported DACRA dosing, whereas increasing dosing concentration to 50 and 500 mg/kg may further improve preservation of insulin secretion compared with 5 mg/kg in diabetic ZDF rats. SIGNIFICANCE STATEMENTHere we show that KeyBiosciencePeptide (KBP)-066 induces an equally potent body weight loss across a broad dose range in obese rats. However, higher dosing of KBP-066 may improve insulin action in diabetic rats both as preventive and interventive treatment.

show abstract

Effect of Acute and Chronic Administration of Calcitonin on Serum Glucose in Patients with Paget's Disease of Bone*

Cited by 17 publications

References 14 publications

Calcitonin Gene—Related Peptide and Induction of Hyperglycemia in Conscious Rats In Vivo

Calcitonin Gene—Related Peptide and Induction of Hyperglycemia in Conscious Rats In Vivo

Oral salmon calcitonin – pharmacology in osteoporosis

The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action

Contact Info

Product

Resources

About